Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer

Wang,Chunxia; Xie,Jingping; Guo,Jiasong; Manning,H.  Charles; Gore,John  C.; Guo,Ning

doi:10.3892/or.2012.1951

Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer

Authors:
- Chunxia Wang
- Jingping Xie
- Jiasong Guo
- H. Charles Manning
- John C. Gore
- Ning Guo
View Affiliations

Affiliations: Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou 510515, P.R. China, Institute of Imaging Science, Vanderbilt University, Nashville, TN 37232, USA, Department of Embryology and Histology, Southern Medical University, Guangzhou 510515, P.R. China
Published online on: August 6, 2012 https://doi.org/10.3892/or.2012.1951
Pages: 1301-1308

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer (CRC) is a major cause of cancer-related mortality in the world. Recently, a number of studies have demonstrated that cancer stem cells (CSCs) present in colorectal cancer tissues, are responsible for resistance to conventional therapies. Therefore, effective recognition of CSCs is of great importance. In the present study, to explore the potential characterizations of CSCs by the expression of specific cell surface markers such as CD133 and CD44, we screened six CRC cell lines using western blotting, immunofluorescence and flow cytometry. SW620, one of the six cell lines analyzed, was sorted into four subpopulations by fluorescence activated cell sorting (FACS). The capability of colony formation, proliferation rate, apoptosis, drug resistance, as well as their migratory and invasion potential were detected. The results revealed that the combination of CD44 and CD133 correlates with the features of CSCs in SW620 cells. CD44 positive cells showed more robust colony formation, higher proliferation, less spontaneous apoptosis, a higher resistance to drug-induced cell death, and were enriched after drug treatment. Among CD44 positive SW620 cells, the CD133 negative subpopulation was more migratory and invasive, which means that CD44+CD133- correlates with most of features proposed for CSCs. Overall, the data presented herein showed that CRCs have a wide range of expression for CD44 and CD133; it is unlikely the CSCs can be characterized by any single marker or the same set of markers for all colon cancer cells. For SW620 cells, the CSCs are likely represented by the CD44+CD133- surface marker. This finding of CSC markers represented by one positive and one negative is in line with CSCs in other tumors, such as CD34+CD38- for acute myeloid leukemia; CD44+CD24- for breast and pancreatic tumors. The absence of surface molecule(s) on CSCs will make it even more difficult to track and target this group of minority cells.

View Figures

View References

1	Kinzler KW and Vogelstein B: Lessons from hereditary colorectal cancer. Cell. 87:159–170. 1996. View Article : Google Scholar : PubMed/NCBI
2	Bonnet D and Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI
3	Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
4	Li C, Heidt DG, Dalerba P, et al: Identification of pancreatic cancer stem cells. Cancer Res. 67:1030–1037. 2007. View Article : Google Scholar : PubMed/NCBI
5	O’Brien CA, Pollett A, Gallinger S and Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 445:106–110. 2007.PubMed/NCBI
6	Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al: Identification and expansion of human colon-cancer-initiating cells. Nature. 445:111–115. 2007. View Article : Google Scholar : PubMed/NCBI
7	Dalerba P, Dylla SJ, Park IK, et al: Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA. 104:10158–10163. 2007. View Article : Google Scholar : PubMed/NCBI
8	Du L, Wang H, He L, et al: CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res. 14:6751–6760. 2008. View Article : Google Scholar : PubMed/NCBI
9	Takaishi S, Okumura T, Tu S, et al: Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells. 27:1006–1020. 2009. View Article : Google Scholar : PubMed/NCBI
10	Huang EH, Hynes MJ, Zhang T, et al: Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res. 69:3382–3389. 2009. View Article : Google Scholar : PubMed/NCBI
11	Shmelkov SV, Butler JM, Hooper AT, et al: CD133 expression is not restricted to stem cells, and both CD133⁺ and CD133⁻ metastatic colon cancer cells initiate tumors. J Clin Invest. 118:2111–2120. 2008.PubMed/NCBI
12	Bao S, Wu Q, Sathornsumetee S, et al: Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 66:7843–7848. 2006. View Article : Google Scholar : PubMed/NCBI
13	Al Dhaybi R, Sartelet H, Powell J and Kokta V: Expression of CD133⁺ cancer stem cells in childhood malignant melanoma and its correlation with metastasis. Mod Pathol. 23:376–380. 2010.
14	Artells R, Moreno I, Diaz T, et al: Tumour CD133 mRNA expression and clinical outcome in surgically resected colorectal cancer patients. Eur J Cancer. 46:642–649. 2010. View Article : Google Scholar : PubMed/NCBI
15	Baba T, Convery PA, Matsumura N, et al: Epigenetic regulation of CD133 and tumorigenicity of CD133⁺ ovarian cancer cells. Oncogene. 28:209–218. 2009. View Article : Google Scholar : PubMed/NCBI
16	Tirino V, Desiderio V, Paino F, et al: Human primary bone sarcomas contain CD133⁺ cancer stem cells displaying high tumorigenicity in vivo. FASEB J. 25:2022–2030. 2011. View Article : Google Scholar : PubMed/NCBI
17	Griguer CE, Oliva CR, Gobin E, et al: CD133 is a marker of bioenergetic stress in human glioma. PLoS ONE. 3:e36552008. View Article : Google Scholar : PubMed/NCBI
18	Bidlingmaier S, Zhu X and Liu B: The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J Mol Med. 86:1025–1032. 2008. View Article : Google Scholar : PubMed/NCBI
19	Futschik M, Jeffs A, Pattison S, et al: Gene expression profiling of metastatic and nonmetastatic colorectal cancer cell lines. Genome Lett. 1:26–34. 2002. View Article : Google Scholar
20	Madjd Z, Mehrjerdi AZ, Sharifi AM, Molanaei S, Shahzadi SZ and Asadi-Lari M: CD44⁺ cancer cells express higher levels of the anti-apoptotic protein Bcl-2 in breast tumours. Cancer Immun. 9:42009.
21	Hao JL, Cozzi PJ, Khatri A, Power CA and Li Y: CD147/EMMPRIN and CD44 are potential therapeutic targets for metastatic prostate cancer. Curr Cancer Drug Targets. 10:287–306. 2010. View Article : Google Scholar : PubMed/NCBI
22	Huerta S, Harris DM, Jazirehi A, et al: Gene expression profile of metastatic colon cancer cells resistant to cisplatin-induced apoptosis. Int J Oncol. 22:663–670. 2003.PubMed/NCBI
23	Kawamoto H, Yuasa T, Kubota Y, et al: Characteristics of CD133(+) human colon cancer SW620 cells. Cell Transplant. 19:857–864. 2010.
24	Todaro M, Alea MP, Di Stefano AB, et al: Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell. 1:389–402. 2007. View Article : Google Scholar : PubMed/NCBI
25	Haraguchi N, Ohkuma M, Sakashita H, et al: CD133⁺CD44⁺ population efficiently enriches colon cancer initiating cells. Ann Surgical Oncol. 15:2927–2933. 2008.
26	Miletti-Gonzalez KE, Chen S, Muthukumaran N, et al: The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer. Cancer Res. 65:6660–6667. 2005. View Article : Google Scholar : PubMed/NCBI
27	Wiranowska M, Ladd S, Smith SR and Gottschall PE: CD44 adhesion molecule and neuro-glial proteoglycan NG2 as invasive markers of glioma. Brain Cell Biol. 35:159–172. 2006. View Article : Google Scholar : PubMed/NCBI
28	Kojima M, Ishii G, Atsumi N, Fujii S, Saito N and Ochiai A: Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. Cancer Sci. 99:1578–1583. 2008. View Article : Google Scholar : PubMed/NCBI
29	Bendardaf R, Algars A, Elzagheid A, et al: Comparison of CD44 expression in primary tumours and metastases of colorectal cancer. Oncol Rep. 16:741–746. 2006.PubMed/NCBI
30	Huh JW, Kim HR, Kim YJ, et al: Expression of standard CD44 in human colorectal carcinoma: association with prognosis. Pathol Int. 59:241–246. 2009. View Article : Google Scholar : PubMed/NCBI
31	Liu C, Kelnar K, Liu B, et al: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 17:211–215. 2011. View Article : Google Scholar : PubMed/NCBI
32	Gao AC, Lou W, Dong JT and Isaacs JT: CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res. 57:846–849. 1997.PubMed/NCBI
33	Abetamann V, Kern HF and Elsasser HP: Differential expression of the hyaluronan receptors CD44 and RHAMM in human pancreatic cancer cells. Clin Cancer Res. 2:1607–1618. 1996.PubMed/NCBI